Eprosartan proves its worth for hypertension in elderly.

The article reports on a cost analysis conducted in Spain on the hypertension drug eprosartan. According to researchers, despite its high acquisition cost, the overall costs of treating hypertension with eprosartan are similar to those of diuretics. The acquisition cost and costs associated with eprosartan and diuretics were compared. It was concluded that eprosartan may contribute to improved prescription compliance.